Inappropriate Antibiotic Prescribing Common for Women With UTIs
Many women receive prescriptions for inappropriate agents or durations; rural women more likely to receive Rx with inappropriately long duration
Urologic Disorders
Imfinzi Indication for Urothelial Carcinoma Withdrawn
Under the accelerated approval program, if a confirmatory trial does not show clinical benefit, the FDA can take steps to remove the drug or indication.
Certain Prostate Drugs Tied to Risk for Parkinson Disease
Use of glycolysis-enhancing drugs terazosin, doxazosin, or alfuzosin tied to lower risk for developing Parkinson disease than use of tamsulosin
Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC
Adding Vibegron to BPH Meds Safe, Effective for Overactive Bladder
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
MPR Weekly Dose Podcast Episode 68
This week we cover a caution about remdesivir; New and updated Emergency Use Authorizations; And new approvals in sleep apnea and for Botox.
Botox Approved for Neurogenic Detrusor Overactivity in Pediatric Patients
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.
Iron Replacement Therapy Triferic AVNU Now Available
Triferic is an iron maintenance therapy that delivers between 5 to 7mg of iron with every hemodialysis treatment and maintains hemoglobin without increasing ferritin.
Phosphate Binder Found to Raise Blood Pressure in CKD
Investigators found a clinically significant difference in systolic blood pressure among patients with stage 3b to 4 chronic kidney disease taking and not taking lanthanum carbonate.
Lupkynis Approved for Active Lupus Nephritis
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
